• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Savara Inc.

    11/14/25 4:27:38 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SVRA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)


    Savara Inc

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    805111101

    (CUSIP Number)


    Stephanie Brecher
    New Enterprise Associates, 1954 Greenspring Drive, Suite 600
    Timonium, MD, 21093
    (410)842-4000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    11/12/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    Growth Equity Opportunities 17, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    New Enterprise Associates 17, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    NEA Partners 17, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    NEA 17 GP, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    Forest Baskett
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    Ali Behbahani
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    Carmen Chang
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    Anthony A. Florence, Jr.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    Mohamad H. Makhzoumi
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    Edward T. Mathers
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    Scott D. Sandell
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    Paul Walker
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    805111101


    1 Name of reporting person

    Rick Yang
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    24,471,264.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    24,471,264.00
    11Aggregate amount beneficially owned by each reporting person

    24,471,264.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.001 per share
    (b)Name of Issuer:

    Savara Inc
    (c)Address of Issuer's Principal Executive Offices:

    1717 Langhorne Newtown Road, Suite 300, Langhorne, PENNSYLVANIA , 19047.
    Item 1 Comment:
    This Amendment No. 3 ("Amendment No. 3") to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on March 25, 2021 (the "Schedule 13D"), Amendment No. 1 filed on July 26, 2023 ("Amendment No. 1") and Amendment No. 2 filed on August 14, 2024 ("Amendment No. 2") relating to the Common Stock of the Issuer. Certain terms used but not defined in this Amendment No. 3 have the meanings assigned thereto in the Schedule 13D (including Amendment No. 1 and Amendment No. 2 thereto). Except as specifically provided herein, this Amendment No. 3 does not modify any of the information previously reported on the Schedule 13D (including Amendment No. 1 and Amendment No. 2 thereto). This Amendment No. 3 is being filed to report that the beneficial ownership of Common Stock by the Reporting Persons (as defined below) has decreased by more than 1% as a result of an increase in the number of Common Stock outstanding.
    Item 2.Identity and Background
    (a)
    Growth Equity Opportunities 17, LLC ("GEO"); New Enterprise Associates 17, L.P. ("NEA 17") which is the sole member of GEO; NEA Partners 17, L.P. ("NEA Partners 17"), which is the sole general partner of NEA 17; and NEA 17 GP, LLC ("NEA 17 LLC" and, together with NEA Partners 17, the "Control Entities"), which is the sole general partner of NEA Partners 17; and Forest Baskett ("Baskett"), Ali Behbahani ("Behbahani"), Carmen Chang ("Chang"), Anthony A. Florence, Jr. ("Florence"), Mohamad H. Makhzoumi ("Makhzoumi"), Edward T. Mathers ("Mathers"), Scott D. Sandell ("Sandell"), Paul Walker ("Walker"), and Rick Yang ("Yang") (together, the "Managers"). The Managers are the managers of NEA 17 LLC. The persons named in this Item 2 are referred to individually herein as "Reporting Person" and collectively as the "Reporting Persons."
    (b)
    The address of the principal business office of GEO, NEA 17, each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett, Behbahani, Chang, Makhzoumi, Walker and Yang is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, CA 94025. The address of the principal business office of Florence and Mathers is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10011.
    (c)
    The principal business of GEO and NEA 17 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 17 is to act as the sole general partner of NEA 17. The principal business of NEA 17 LLC is to act as the sole general partner of NEA Partners 17. The principal business of each of the Managers is to manage the Control Entities, NEA 17 and a number of affiliated partnerships with similar businesses.
    (d)
    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (e)
    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    GEO and NEA 17 LLC are limited liability companies organized under the laws of the State of Delaware. NEA 17 and NEA Partners 17 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Not applicable.
    Item 4.Purpose of Transaction
     
    GEO acquired the GEO Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, GEO and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) Any action similar to any of those enumerated above.
    Item 5.Interest in Securities of the Issuer
    (a)
    GEO is the record owner of the GEO Shares. As the sole member of GEO, NEA 17 may be deemed to own beneficially the GEO Shares. As the general partner of NEA 17, NEA Partners 17 may be deemed to own beneficially the GEO Shares. As the sole general partner of NEA Partners 17, NEA 17 LLC may be deemed to beneficially own the GEO Shares. As members of NEA 17 LLC, each of the Managers may be deemed to own beneficially the GEO Shares. Each Reporting Person disclaims beneficial ownership of the GEO Shares other than those shares which such person owns of record. The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Peron's cover sheet. Such percentage was calculated based on 203,467,845 shares of Common Stock reported by the Issuer to be outstanding as of November 12, 2025 on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025.
    (b)
    Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
    (c)
    None of the Reporting Persons have effected any transaction in the last 60 days.
    (d)
    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Not applicable.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1 - Agreement regarding filing of joint Schedule 13D. Exhibit 2 - Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Growth Equity Opportunities 17, LLC
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:11/14/2025
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:11/14/2025
     
    New Enterprise Associates 17, L.P.
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:11/14/2025
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:11/14/2025
     
    NEA Partners 17, L.P.
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:11/14/2025
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:11/14/2025
     
    NEA 17 GP, LLC
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:11/14/2025
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:11/14/2025
     
    Forest Baskett
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Forest Baskett
    Date:11/14/2025
     
    Ali Behbahani
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Ali Behbahani
    Date:11/14/2025
     
    Carmen Chang
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Carmen Chang
    Date:11/14/2025
     
    Anthony A. Florence, Jr.
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr.
    Date:11/14/2025
     
    Mohamad H. Makhzoumi
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi
    Date:11/14/2025
     
    Edward T. Mathers
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Edward T. Mathers
    Date:11/14/2025
     
    Scott D. Sandell
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Scott D. Sandell
    Date:11/14/2025
     
    Paul Walker
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Paul Walker
    Date:11/14/2025
     
    Rick Yang
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Rick Yang
    Date:11/14/2025
    Comments accompanying signature:
    This Amendment No. 3 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.
    Get the next $SVRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SVRA

    DatePrice TargetRatingAnalyst
    10/20/2025$7.00Overweight
    Wells Fargo
    8/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    5/29/2025$2.00Buy → Neutral
    H.C. Wainwright
    12/20/2024$8.00Overweight
    Wells Fargo
    11/13/2024$7.00 → $5.00Outperform → In-line
    Evercore ISI
    2/15/2024$8.00Mkt Outperform
    JMP Securities
    11/7/2023$7.00Buy
    Guggenheim
    5/16/2023$2.00 → $4.00Hold → Buy
    Jefferies
    More analyst ratings

    $SVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Savara with a new price target

    Wells Fargo initiated coverage of Savara with a rating of Overweight and set a new price target of $7.00

    10/20/25 8:03:17 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Savara from Neutral to Buy and set a new price target of $5.00

    8/15/25 9:10:16 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Savara from Buy to Neutral and set a new price target of $2.00

    5/29/25 8:15:44 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Savara Announces Participation in Upcoming Investor Healthcare Conferences

    Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host one on one meetings and participate in fireside chats at two upcoming healthcare conferences. Fireside Chats: Piper Sandler 37th Annual Healthcare Conference December 2, 2025, 2:30pm ET Evercore ISI 8th Annual Healthcare Conference December 4, 2025, 10:00am ET The live webcasts and subsequent replays will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on r

    11/20/25 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

    -- On Track to Resubmit the Biologics License Application (BLA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) in December and Will Request Priority Review -- -- Expect to Submit the MOLBREEVI Marketing Authorization Applications (MAA) for Autoimmune PAP to the European Medicines Agency (EMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in 1Q 2026 -- -- Recently Strengthened Balance Sheet with ~$149.5M Equity Financing, Which Added ~$140M to the ~$124M in Cash, Cash Equivalents, and Short-Term Investments Reported as of September 30, 2025, and Announced $75M Royalty Funding Agreement to Support Potential MOLBREEVI Launch -- Savara

    11/12/25 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Announces Participation in Upcoming Investor Healthcare Conferences

    Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and participate in fireside chats at two upcoming healthcare conferences. Fireside Chats: Guggenheim 2nd Annual Healthcare Innovation Conference November 10, 2025, 8:30 a.m. ET Jefferies London Healthcare Conference November 19, 2025, 12:00 p.m. GMT The live webcasts and subsequent replays will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara  Savara is a clinical stage biopharmaceutical company focused

    11/3/25 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Savara Inc.

    SCHEDULE 13D/A - Savara Inc (0001160308) (Subject)

    11/14/25 4:27:38 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Savara Inc.

    10-Q - Savara Inc (0001160308) (Filer)

    11/12/25 4:05:54 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Savara Inc.

    424B5 - Savara Inc (0001160308) (Filer)

    10/30/25 4:43:56 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hawkins Richard J exercised 5,860 shares at a strike of $1.46, increasing direct ownership by 5% to 121,326 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    11/17/25 4:38:18 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Wasfi Yasmine was granted 35,000 shares, increasing direct ownership by 23% to 190,000 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    10/22/25 8:47:47 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Wasfi Yasmine claimed ownership of 155,000 shares (SEC Form 3)

    3 - Savara Inc (0001160308) (Issuer)

    10/22/25 8:44:51 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hawkins Richard J bought $98,572 worth of shares (48,225 units at $2.04), increasing direct ownership by 72% to 115,466 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/23/25 2:39:22 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mccracken Joseph S bought $20,825 worth of shares (10,000 units at $2.08), increasing direct ownership by 4% to 260,837 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/2/25 7:59:29 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ramsay David A bought $416,250 worth of shares (150,000 units at $2.77), increasing direct ownership by 6% to 2,513,642 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    4/1/25 7:00:04 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Leadership Updates

    Live Leadership Updates

    View All

    Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

    Mr. Parker has More Than 25 Years of Commercial Leadership Experience and has Launched Multiple Rare Disease Products Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of Braden Parker as Chief Commercial Officer, effective immediately. Mr. Parker is a seasoned global commercial leader with more than 25 years of experience in the healthcare and biotech industry. Throughout his career, he has developed and executed global commercial plans, including market expansion activities, built high-performance teams, and launched multiple successful rare disease products. Mr. Parker is responsible

    9/24/24 8:05:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

     Pivotal Phase 3 IMPALA-2 Trial Remains On-Track, Top Line Data Expected End of 2Q 2024 IMPALA-2 is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease Received Acceptance from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) on a Revised Pediatric Investigation Plan (PIP) for Molgramostim in aPAP Appoints Raymond Pratt, M.D., Chief Medical Officer Company Ends Quarter with ~$134M, Believes it is Sufficiently Capitalized Through 2025 Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory disease

    11/10/22 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Announces Resignation of Chief Medical Officer

    Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022. "We appreciate Dr. Chowdhury's contributions during his tenure with the company," said Matt Pauls, Chair and CEO, Savara. "His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future." "I am pleased to have been part of the Savara team and wish the company success in the continued development of molgramostim for the treatment of the rare lung

    8/26/22 8:05:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Savara Inc.

    SC 13G - Savara Inc (0001160308) (Subject)

    11/27/24 11:01:58 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Savara Inc.

    SC 13G/A - Savara Inc (0001160308) (Subject)

    11/14/24 5:48:34 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Savara Inc.

    SC 13G/A - Savara Inc (0001160308) (Subject)

    11/12/24 10:25:33 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Financials

    Live finance-specific insights

    View All

    Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) Statistically Significant Improvement in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24 (Secondary Endpoint) 97% of Patients Completed Double-Blind Treatment Through Week 48 with No Trial Drug Related Adverse Events Leading to Discontinuation 100% of Patients Completing the 48-Week Double-Blind Period Elected to Participate in the 96-Week Open-Label Period Company Plans to Complete BLA Submission in 1H 2025 Company to Host Webcast Conference Call Today, Ju

    6/26/24 6:30:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Conference Call to Take Place Tomorrow, Wednesday, June 26, 2024, at 8:00am ET Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with aPAP. The Company plans to issue a press release sharing the top line results at approximately 6:30am ET tomorrow, prior to the start of the c

    6/25/24 8:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care